Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omecamtiv mecarbil exercise capacity study in heart failure with reduced ejection fraction
2018-001233-40Phase 3Completed
- Sponsor
- Amgen
- Start
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in heart failure with reduced ejection fraction (HFrEF) and chronic heart failure (CHF) comparing Omecamtiv mecarbil with Placebo (2 arms). Primary endpoint: Change in peak VO2 on CPET from baseline to Week 20. Started Jan 2019; status: completed.
02
Drugs
omecamtiv mecarbil
03
Conditions
heart failure with reduced ejection fraction (HFrEF)chronic heart failure (CHF)
Beyond the preview
Go deeper on 2018-001233-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001233-40.